Humana Inc. (NYSE:HUM) Shares Bought by Ilmarinen Mutual Pension Insurance Co

Ilmarinen Mutual Pension Insurance Co raised its holdings in shares of Humana Inc. (NYSE:HUM) by 46.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,500 shares of the insurance provider’s stock after purchasing an additional 3,000 shares during the period. Ilmarinen Mutual Pension Insurance Co’s holdings in Humana were worth $2,410,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. FPC Investment Advisory Inc. purchased a new stake in Humana in the fourth quarter valued at about $27,000. Centricity Wealth Management LLC acquired a new position in shares of Humana in the 4th quarter valued at $30,000. LFA Lugano Financial Advisors SA lifted its position in Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after acquiring an additional 45 shares during the period. OFI Invest Asset Management acquired a new position in shares of Humana in the fourth quarter valued at about $33,000. Finally, Atwood & Palmer Inc. boosted its position in Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after buying an additional 60 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Trading Down 4.6 %

Shares of Humana stock opened at $253.37 on Friday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The stock’s 50 day simple moving average is $267.58 and its 200-day simple moving average is $271.85. The stock has a market cap of $30.58 billion, a P/E ratio of 25.46, a P/E/G ratio of 2.05 and a beta of 0.62. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46.

Humana (NYSE:HUM) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.40%. The ex-dividend date is Friday, March 28th. Humana’s payout ratio is currently 35.58%.

Wall Street Analyst Weigh In

Several analysts have commented on HUM shares. Royal Bank of Canada restated an “outperform” rating and set a $283.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Barclays upped their price objective on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. Piper Sandler raised their price target on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Truist Financial raised their target price on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research report on Monday, January 6th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $290.00 target price on shares of Humana in a research report on Wednesday, February 12th. Eighteen investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Humana presently has an average rating of “Hold” and an average price target of $280.17.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.